Zacks Investment Research
19 Jan 2026, 15:21 UTC · 40w ago
Verdict
Headline leans bullish. We score CTMX +1.00.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
More positive than 99% of ticker scores this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Shares surged 126.4% over six months following positive strategic updates and encouraging clinical progress.
More negative than 71% of ticker scores this week
The article notes that sales of its drug Avastin have been declining due to biosimilar competition.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 32% of relationship scores this week
[mutual] CytomX is conducting a phase I study evaluating its drug Varseta-M in combination with Roche's Avastin.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
16h ago
−57.5%
Price is moving against the score
$2.29 vs $5.39 close before publication (Jan 16) · not market-adjusted
CTMX chart →
